Drug Profile
QRX 001
Alternative Names: QRX001Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Quoin Pharmaceuticals
- Class Analgesics
- Mechanism of Action NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Postoperative pain
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Postoperative-pain in USA (Transdermal, Patch)
- 27 Nov 2017 Preclinical trials in Postoperative pain in USA (Transdermal)
- 27 Nov 2017 Quoin Pharmaceuticals plans a phase II trial for Postoperative pain in USA (Transdermal) in 2018